(Q34236311)

31 July 2017

title

Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period (English)

1 reference

31 July 2017

1 reference

3

Arier Lee

1 reference

31 July 2017

Héctor Dueñas

1

1 reference

31 July 2017

Alan J M Brnabic

2

1 reference

31 July 2017

Angel L Montejo

4

1 reference

31 July 2017

Siva Prakash

5

1 reference

31 July 2017

Ma Luz S Casimiro-Querubin

6

1 reference

31 July 2017

Mohamed Khaled

7

1 reference

31 July 2017

Martin Dossenbach

8

1 reference

31 July 2017

Joel Raskin

9

1 reference

31 July 2017

language of work or name

1 reference

1 November 2011

1 reference

International Journal of Psychiatry in Clinical Practice

31 July 2017

published in

1 reference

31 July 2017

volume

15

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

242-254

1 reference

Sexual dysfunction in the United States: prevalence and predictors

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Effects of SSRIs on sexual function: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Antidepressant-induced sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Pharmacogenetics studies in STAR*D: strengths, limitations, and results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Sexual side-effects of contemporary antidepressants: review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Effects of duloxetine on painful physical symptoms associated with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Duloxetine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

Sexual dysfunction and physicians' perception in medicated patients with major depression in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2011.590209

10.3109/13651501.2011.590209

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference